

OptiPrep™ Mini-Review MV03

Purification and analysis of *Herpesviridae* viruses and herpes virus vectors

- ◆ OptiPrep™ is a sterile 60% (w/v) solution of iodixanol in water, density = 1.32 g/ml
- ◆ This Mini-Review principally provides (in Section 2) a bibliography of all those papers reporting the use of OptiPrep™ in the purification and analysis of herpes simplex virus. Section 1 briefly summarizes the advantages of using OptiPrep™; the gradient strategies that are available and the technical data that is available from Axis-Shield.

1. Technical background to the use of OptiPrep™

1a. Background

In all comparative studies between CsCl and iodixanol, the recovery of virus infectivity is much higher and the particle:infectivity ratio much lower when viruses are purified in iodixanol. Although sucrose is generally less deleterious to viral infectivity than CsCl, it can nevertheless also have serious effects on certain important aspects of viral function; in particular the loss of surface glycoproteins from enveloped viruses has been noted [1] and with HIV-1 the disorganization of the Gag sub-membrane layer [2]. The loss of surface glycoprotein may be related to its viscosity, which, in solutions of the same density, is much higher than that of iodixanol. Most iodixanol gradients can also be made isoosmotic over the entire density range.

Like CsCl, sucrose must be dialyzed before infectivity can be measured. In contrast both infectivity measurements using cultured cells and many add-on techniques can be performed without dialysis of iodixanol. Combined with the availability of OptiPrep™ as a sterile solution, this makes the use of OptiPrep™ for virus purification and assembly analysis much more convenient than the use of either CsCl or sucrose. The only analytical technique for which removal of the iodixanol is essential is electron microscopy. Consequently iodixanol is being increasingly used for the purification of hepatitis C virus particles from lysed cultured cells, from conditioned culture medium or from plasma samples from infected patients.

1b. Solution preparation

Isoosmotic solutions for making gradients may be prepared simply by diluting OptiPrep™ with a HEPES- or Tris-buffered saline solution; sometimes 1 mM EDTA is included. The ability to produce sterile solutions that are isoosmotic by this procedure, greatly facilitates the procedure, Nycodenz® solutions must be produced by dissolution of a powder and then sterilized.

1c. Gradient strategy

A wide range of iodixanol density gradient strategies is available. It can be used in the standard manner as a pre-formed discontinuous or continuous gradient or as self-generated gradient. The preformed gradients, broadly speaking, cover the range 10-40% (w/v) iodixanol. Most of them are top-loaded with the crude virus preparation. If however the virus has been concentrated by sedimenting onto a cushion of dense iodixanol, it may be prudent consider bottom loading the virus. It may be difficult to harvest the virus from the top of a dense cushion and maintain a virus suspension that has a sufficiently low density to allow its easy layering on top of a gradient. With bottom loading (flotation gradient) this is never a problem.

Herpes simplex virus particles have also been analyzed in self-generated gradients of iodixanol. This very simple technique, which has been used for a number of other viruses, requires only adjustment of the crude virus suspension to 25% (w/v) iodixanol. The formation of a self-generated gradient is most efficiently carried out in a vertical or near-vertical rotor at approx 350,000 g for 2-3 h but a fixed-angle rotor (approx. 10 ml tube size) may be substituted for longer times. The low virus concentration at the start of the centrifugation and the lack of any liquid/liquid interfaces may optimize resolution of virus particles from contaminants.

1d. References

1. Palker, T.J. (1990) *Mapping of epitopes on human T-cell leukemia virus type 1 envelope glycoprotein* In: Human Retrovirology: HTLV (ed. Blattner, W.A.) Raven Press, NY, pp 435-445
2. Kol, N., Tsvitov, M., Hevroni, L., Wolf, S.G., Pang, H-B., Kay, M.S. and Rousso, I. (2010) *The effect of purification method on the completeness of the immature HIV-1 Gag shell* J. Virol. Methods **169**, 244-247

1e. OptiPrep™ Application Sheets

Detailed protocols for the isolation of the herpes virus may be accessed from the Axis-Shield OptiPrep™ Applications flash-drive or from the following website: www.axis-shield-density-gradient-media.com, click on “Methodology” then “Viruses” to open up the Virus Index. Other relevant OptiPrep™ Application Sheets may also be accessed from the top of the Index.

◆ Herpes virus purification in pre-formed gradients	OptiPrep™ Application Sheet V09
◆ Herpes virus purification in self-generated gradients	OptiPrep™ Application Sheet V08
◆ Preparation of density gradient solutions	OptiPrep™ Application Sheet V01
◆ Preparation of continuous and discontinuous gradients	OptiPrep™ Application Sheet V02
◆ Preparation of self-generated gradients	OptiPrep™ Application Sheet V03
◆ Harvesting gradients	OptiPrep™ Application Sheet V04
◆ Analysis of gradients	OptiPrep™ Application Sheet V05
◆ Concentration of virus samples	OptiPrep™ Application Sheet V06

2. Bibliography

- ◆ The references have been divided into research topic and within each section they are listed alphabetically by first author; multiple entries on the same first author are listed chronologically. **Papers reporting the study of Epstein-Barr virus are given in separate section, see pp 6-7.**

Angiogenesis

Arafat, W.O., Casado, E., Wang, M., Alvarez, R.D., Siegal, G.P., Glorioso, J.C., Curiel, D.T. and Gomez-Navarro, J. (2000) *Genetically modified CD34⁺ cells exert a cytotoxic bystander effect on human endothelial and cancer cells* Clin. Cancer Res., **6**, 4442-4448

Berto, E., Bozac, A., Volpi, I., Lanzoni, I., Vasquez, F., Melara, N., Manservigi, R. and Marconi, P. (2007) *Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth* Cancer Gene Ther., **14**, 791-801

Gomez-Navarro, J.L., Contreras, J.L., Arafat, W., Jiang, X.L., Krisky, D., Oligino, T., Marconi, P., Hubbard, B., Glorioso, J.C., Curiel, D.T. and Thomas, J.M. (2000) *Genetically modified CD34⁺ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model* Gene Ther., **7**, 43-52

Shah, A.C., Price, K.H., Parker, J.N., Samuel, S.L., Meleth, S., Cassady, K.A., Gillespie, G.Y., Whitley, R.J. and Markert, J.M. (2006) *Serial passage through human glioma xenografts selects for a $\Delta\gamma 134.5$ herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors* J. Virol., **80**, 7308-7315

Assembly/cell interactions

Bosse, J.B., Bauerfeind, R., Popilka, L., Marcinowski, L., Taeglich, M., Jung, C., Striebinger, H., von Einem, J., Gaul, U., Walther, P., Koszinowski, U.H. and Ruzsics, Z. (2012) *A beta-herpesvirus with fluorescent capsids to study transport in living cells* PLoS One, **7**: e40585

Jambunathan, N., Chowdhury, S., Subramanian, R., Chouljenko, V.N., Walker, J.D. and Kousoulas, K.G. (2011) *Site-specific proteolytic cleavage of the amino terminus of herpes simplex virus glycoprotein K on virion particles inhibits virus entry* J. Virol., **85**, 12910–12918

Jambunathan, N., Charles, A-S., Subramanian, R., Saied, A.A., Naderi, M., Rider, P., Brylinski, M., Chouljenko, V.N. and Kousoulas, K.G. (2016) *Deletion of a predicted β -sheet domain within the amino terminus of herpes simplex virus glycoprotein K conserved among alphaherpesviruses prevents virus entry into neuronal axons* J. Virol., **90**, 2230-2239

Exosome secretion profiles

Heikkilä, O., Ryödi, E. and Hukkanen, V. (2016) *The $\gamma 134.5$ neurovirulence gene of herpes simplex virus 1 modifies the exosome secretion profile in epithelial cells* J. Virol., **90**, 10981-10984

Gene expression

St. Leger, A.J., Peters, B., Sidney, J., Sette, A. and Hendricks, R.L. (2011) *Defining the herpes simplex virus-specific CD8⁺ T cell repertoire in C57BL/6 mice* J. Immunol., **186**, 3927–3933

Glycoprotein K

Jambunathan, N., Charles, A.-S., Subramanian, R., Saied, A.A., Naderi, M., Rider, P., Brylinski, M., Chouljenko, V.N. and Kousoulas, K.G. (2016) *Deletion of a predicted β -sheet domain within the amino terminus of herpes simplex virus glycoprotein K conserved among alphaherpesviruses prevents virus entry into neuronal axons* J. Virol., **90**, 2230-2239

HIV infection, in

Caselli, E., Galavan, M., Cassai, E., Caruso, A., Sighinolfi, L. and Di Luca, D. (2005) *Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells* Blood, **106**, 2790-2797

HLA modification

Caselli, E., Campioni, D., Cavazzini, F., Gentili, V., Bortolotti, D., Cuneo, A., Di Luca, D. and Rizzo, R. (2015) *Acute human herpesvirus-6A infection of human mesothelial cells modulates HLA molecules* Arch. Virol., **160**, 2141–2149

Host cell proteins

Hammarstedt, M., Ahlqvist, J., Jacobson, S., Garoff, H. and Fogdell-Hahn, A. (2007) *Purification of infectious human herpesvirus 6A virions and association of host cell proteins* Virol J. **4**:101

Immunosurveillance

Frank, G.M., Lepisto, A.J., Freeman, M.L., Sheridan, B.S., Cherpes, T.L. and Hendricks, R.L. (2010) *Early CD4⁺ T cell help prevents partial CD8⁺ T cell exhaustion and promotes maintenance of herpes simplex virus 1 latency* J. Immunol., **184**, 277-286

Frank, G.M., Buela, K.-A.G., Maker, D.M., Harvey, S.A.K. and Hendricks, R.L. (2012) *Early responding dendritic cells direct the local NK response to control herpes simplex virus 1 infection within the cornea* J. Immunol., **188**, 1350–1359

Infectivity studies

Ahlquist, J., Hammarstadt, M., Jacobson, S., Garoff, H. and Fogdell-Hahn, A. (2006) *Identification of host cell proteins in purified infectious humanherpesvirus 6A (HHV-6A) viral particles* J. Neuroimmunol., **178**, Suppl. 1, 114

Avanzi, S., Leoni, V., Rotola, A., Alviano, F., Solimando, L., Lanzoni, G., Bonsi, L., Di Luca, D., Marchionni, C., Alvisi, G. and Ripalti, A. (2013) *Susceptibility of human placenta derived mesenchymal stromal/stem cells to human herpesviruses infection* PLoS One, **8**: e71412

Bozac, A., Berto, E., Vasquez, F., Grandi, P., Caputo, A., Manservigi, R., Ensoli, B. and Marconi, P. (2006) *Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses* Vaccine, **24**, 7148-7158

Caselli, E., Fiorentini, S., Amici, C., Di Luca, D., Caruso, A. and Santoro, M.G. (2007) *Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NF- κ B pathway* Blood, **109**, 2718-2726

Caselli, E., Campioni, D., Cavazzini, F., Gentili, V., Bortolotti, D., Cuneo, A., Di Luca, D. and Rizzo, R. (2015) *Acute human herpesvirus-6A infection of human mesothelial cells modulates HLA molecules* Arch. Virol., **160**, 2141–2149

Decman, V., Kinchington, P.R., Harvey, S.A. and Hendricks, R.L. (2005) *Gamma interferon can block herpes simplex virus type 1 reactivation from latency, even in the presence of late gene expression* J. Virol., **79**, 10339-10347

Divito, S.J. and Hendricks, R.L. (2008) *Activated inflammatory infiltrate in HSV-1-infected corneas without Herpes stromal keratitis* Invest. Ophthalmol. Vis. Sci., **49**, 1488-1495

Frank, G.M., Buela, K.-A.G., Maker, D.M., Harvey, S.A.K. and Hendricks, R.L. (2012) *Early responding dendritic cells direct the local NK response to control herpes simplex virus 1 infection within the cornea* J. Immunol., **188**, 1350–1359

Lepisto, A.J., Frank, G.M., Xu, M., Stuart, P.M. and Hendricks, R.L. (2006) *CD8 T cells mediate transient Herpes stromal keratitis in CD4-deficient mice* Invest. Ophthalmol. Vis. Sci., **47**, 3400-3409

Lepisto, A.J., Xu, M., Yagita, H., Weinberg, A.D. and Hendricks, R.L. (2007) *Expression and function of the OX40/OX40L costimulatory pair during herpes stromal keratitis* J. Leukoc. Biol., **81**, 766-774

Prabhakaran, K., Sheridan, B.S., Kinchington, P.R., Khann, K.M., Decman, V., Lathrop, K. and Hendricks, R.L. (2005) *Sensory neurons regulate the effector functions of CD8⁺ T cells in controlling HSV-1 latency ex vivo* Immunity, **23**, 515-525

Sheridan, B.S., Khanna, K.M., Frank, G.M. and Hendricks, R.L. (2006) *Latent virus influences the generation and maintenance of CD8⁺ T cell memory* J. Immunol., **177**, 8356-8364

Sheridan, B.S., Cherpès, T.L., Urban, J., Kalinski, P. and Hendricks, R.L. (2009) *Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes* J. Virol., **83**, 2237-2245

St. Leger, A.J., Jeon, S. and Hendricks, R.L. (2013) *Broadening the repertoire of functional herpes simplex virus type 1-specific CD8⁺ T cells reduces viral reactivation from latency in sensory ganglia* J. Immunol., **191**, 2258-2265

Sun, L., St. Leger, A.J., Yu, C-R., He, C., Mahdi, R.M., Chan, C-C., Wang, H., Morse, III, H.C. and Egwuagu, C.E. (2016) *Interferon regulator factor 8 (IRF8) limits ocular pathology during HSV-1 infection by restraining the activation and expansion of CD8⁺ T cells* PLoS ONE 11(5): e0155420

Xu, M., Lepisto, A.J. and Hendricks, R.L. (2004) *CD154 signaling regulates the Th1 response to herpes simplex virus-1 and inflammation in infected corneas* J. Immunol., **173**, 1232-1239

Interferon regulatory factor

Sun, L., St. Leger, A.J., Yu, C-R., He, C., Mahdi, R.M., Chan, C-C., Wang, H., Morse, III, H.C. and Egwuagu, C.E. (2016) *Interferon regulator factor 8 (IRF8) limits ocular pathology during HSV-1 infection by restraining the activation and expansion of CD8⁺ T cells* PLoS ONE 11(5): e0155420

Kaposi's sarcoma associated

Caselli, E., Fiorentini, S., Amici, C., Di Luca, D., Caruso, A. and Santoro, M.G. (2007) *Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NF- κ B pathway* Blood, **109**, 2718-2726

Garrigues, H.J., Rubinchikova, Y.E., DiPersio, C. and Rose, T.M. (2008) *Integrin $\alpha_1\beta_3$ binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor* J. Virol., **82**, 1570-1580

Hahn, A.S., Kaufmann, J.K., Wies, E., Naschberger, E., Panteleev-Ivlev, J., Schmidt, K., Holzer, A., Schmidt, M., Chen, J., König, S., Ensser, A., Myoung, J., Brockmeyer, N.H., Stürzl, M., Fleckenstein, B. and Neipel, F. (2012) *The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma-associated herpesvirus* Nat. Med., **18**, 961-966

Latency, recovery from

Decman, V., Kinchington, P.R., Harvey, S.A. and Hendricks, R.L. (2005) *Gamma interferon can block herpes simplex virus type 1 reactivation from latency, even in the presence of late gene expression* J. Virol., **79**, 10339-10347

Prabhakaran, K., Sheridan, B.S., Kinchington, P.R., Khanna, K.M., Decman, V., Lathrop, K. and Hendricks, R.L. (2005) *Sensory neurons regulate the effector functions of CD8⁺ T cells in controlling HSV-1 latency *in vivo** Immunity, **23**, 515-525

Sheridan, B.S., Khanna, K.M., Frank, G.M. and Hendricks, R.L. (2006) *Latent virus influences the generation and maintenance of CD8⁺ T cell memory* J. Immunol., **177**, 8356-8364

Sheridan, B.S., Cherpès, T.L., Urban, J., Kalinski, P. and Hendricks, R.L. (2009) *Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes* J. Virol., **83**, 2237-2245

St. Leger, A.J., Jeon, S. and Hendricks, R.L. (2013) *Broadening the repertoire of functional herpes simplex virus type 1-specific CD8⁺ T cells reduces viral reactivation from latency in sensory ganglia* J. Immunol., **191**, 2258-2265

Nerve growth factor/neurotrophic factor

Fradette, J., Wolfem D., Goins, W.F., Hunag, S., Flanigan, R.M. and Glorioso, J.C. (2005) *HSV vector-mediated transduction and GDNF secretion from adipose cells* Gene Ther., **12**, 48-58

Goins, W.F., Yoshimura, N., Phelan, M.W., Yokoyama, T., Fraser, M.O., Ozawa, H., Bennett, N., de Groat, W.C., Glorioso, J.C. and Chancellor, M.B. (2001) *Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction* J. Urol., **165**, 1748-1754

Glorioso, J.C. and Fink, D.J. (2002) *Use of HSV vectors to modify the nervous system* Curr. Opin. Drug Discov. Dev., **5**:2

Marconi, P., Zucchini, S., Berto, E., Bozac, A., Paradiso, B., Bregola, G., Grassi, C., Volpi, I., Argani, R., Marzola, A., Manservigi, R. and Simonato, M. (2005) *Effects of defective herpes simplex vectors expressing neurotrophic factors on the proliferation and differentiation of nervous cells *in vivo** Gene Ther., **12**, 559-569

Sasaki K., Chancellor, M.B., Goins, W.F., Phelan, M.W., Glorioso, J.C., de Groat, W.C. and Yoshimura, N. (2004) *Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy* Diabetes, **53**, 2723-2730

rAAV infection, in

Kang, W., Wang, L., Harrell, H., Liu, J., Thomas, D.L., Mayfield, T.L., Scotti, M.M., Ye, G.J., Veres, G. and Knop, D.R. (2009) *An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes* Gene Ther., **16**, 229-239

Mistry, A.R., De Alwis, M., Feudner, E., Ali, R.R. and Thrasher, A.J. (2002) *High-titer stocks of adeno-associated virus from replicating amplicons and herpes vectors* Methods Mol. Med., **69**, 445-460

Toublanc, E., Benraiss, A., Bonnin, D., Blouin, V., Brument, N., Cartier, N., Epstein, A.L., Moullier, P. and Salvetti, A. (2004) *Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines* J. Gene Med., **6**, 555-564

Stromal keratitis

Divito, S.J. and Hendricks, R.L. (2008) *Activated inflammatory infiltrate in HSV-1-infected corneas without Herpes stromal keratitis* Invest. Ophthalmol. Vis. Sci., **49**, 1488-1495

Frank, G.M., Divito, S.J., Maker, D.M., Xu, M. and Hendricks, R.L. (2010) *A novel p40-independent function of IL-12p35 is required for progression and maintenance of herpes stromal keratitis* Invest. Ophthalmol. Vis. Sci., **51**, 3591-3598

Lepisto, A.J., Frank, G.M., Xu, M., Stuart, P.M. and Hendricks, R.L. (2006) *CD8 T cells mediate transient Herpes stromal keratitis in CD4-deficient mice* Invest. Ophthalmol. Vis. Sci., **47**, 3400-3409

Lepisto, A.J., Xu, M., Yagita, H., Weinberg, A.D. and Hendricks, R.L. (2007) *Expression and function of the OX40/OX40L costimulatory pair during herpes stromal keratitis* J. Leukoc. Biol., **81**, 766-774

Xu, M., Lepisto, A.J. and Hendricks, R.L. (2004) *CD154 signaling regulates the Th1 response to herpes simplex virus-1 and inflammation in infected corneas* J. Immunol., **173**, 1232-1239

Yun, H., Rowe, A.M., Lathrop, K.L., Harvey, S.A.K. and Hendricks, R.L. (2004) *Reversible nerve damage and corneal pathology in murine herpes simplex stromal keratitis* J. Virol., **88**, 7870-7880

Suicide gene delivery

Moriuchi, S., Glorioso, J.C., Maruno, M., Izumoto, S., Wolfe, D., Huang, S., Cohen, J.B. and Yoshimine, T. (2005) *Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant I κ B α and HSV thymidine kinase* Cancer Gene Ther., **12**, 487-496 (2005)

Targeting

Argnani, R., Boccafogli, L., Marconi, P.C. and Manservigi, R. (2003) *Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide* Gene Ther., **11**, 1087-1098

T-cell interactions

Sheridan, B.S., Khanna, K.M., Frank, G.M. and Hendricks, R.L. (2006) *Latent virus influences the generation and maintenance of CD8⁺ T cell memory* J. Immunol., **177**, 8356-8364

Sheridan, B.S., Cherpes, T.L., Urban, J., Kalinski, P. and Hendricks, R.L. (2009) *Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes* J. Virol., **83**, 2237-2245

St. Leger, A.J., Peters, B., Sidney, J., Sette, A. and Hendricks, R.L. (2011) *Defining the herpes simplex virus-specific CD8⁺ T cell repertoire in C57BL/6 mice* J. Immunol., **186**, 3927-3933

Trigeminal ganglia infection

Jeon, S., St. Leger, A.J., Cherpes, T.L., Sheridan, B.S. and Hendricks, R.L. (2013) *PD-L1/B7-H1 regulates the survival but not the function of CD8⁺ T cells in herpes simplex virus type 1 latently infected trigeminal ganglia* J. Immunol., **190**, 6277-6286

Vaccination

Çuburu, N., Wang, K., Goodman, K.N., Pang, Y.Y., Thompson, C.D., Lowy, D.R., Cohen, J.I. and Schiller, J.T. (2015) *Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8⁺ T cells and reduces genital disease and viral shedding after HSV-2 challenge* J. Virol., **89**, 83-96

Vector construction and gene delivery

- Argnani, R.**, Boccafogli, L., Marconi, P.C. and Manservigi, R. (2003) *Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide* Gene Ther., **11**, 1087-1098
- Bozac, A.**, Berto, E., Vasquez, F., Grandi, P., Caputo, A., Manservigi, R., Ensoli, B. and Marconi, P. (2006) *Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses* Vaccine, **24**, 7148-7158
- Burton, E.A.**, Huang, S., Goins, W.F. and Glorioso, J.C. (2003) *Use of the herpes simplex viral genome to construct gene therapy vectors* Methods Mol. Med., **76**, 1-31
- Fraefel, C.**, Marconi, P. and Epstein, A.L. (2011) *Herpes simplex virus type 1-derived recombinant and amplicon vectors* In: Viral Vectors for Gene Therapy: Methods and Protocols (eds Merten, O-W. and Al-Rubeai, M.), Methods Mol. Biol., **737**, Springer Science+Business Media, pp 303-343
- Goins, W.F.**, Krisky, D.M., Wolfe, D.P., Fink, D.J. and Glorioso, J.C. (2002) *Development of replication-defective herpes simplex virus vectors* Methods Mol. Med., **69**, 481-507
- Goins, W.F.**, Krisky, D.M., Wechuck, J.B., Huang, S. and Glorioso, J.C. (2008) *Construction and production of recombinant herpes simplex virus vectors* In Methods Mol. Biol., **433** Production and *in vivo* applications of gene transfer (ed. Le Doux, J.M.), Humana Press, Totowa, NJ. pp 97-113
- Goss, J.R.**, Natsume, A., Wolfe, D., mata, M., Glorioso, J.C. and Fink, D. (2004) *Delivery of herpes simplex virus-based vectors to the nervous system* Methods Mol. Biol., **246**, 309-322 (2004)
- Marconi, P.** and Manservigi, R. (2014) *Herpes simplex virus growth, preparation, and assay* In Methods Mol. Biol., **1144**, Herpes Simplex Virus: Methods and Protocols, (ed. Diefenbach, R.J. and Fraefel, C.) Springer Science+Business Media, New York pp 19-29
- Marconi, P.**, Fraefel, C. and Epstein, A.L. (2015) *Herpes simplex virus type 1 (HSV-1)-derived recombinant vectors for gene transfer and gene therapy* In Methods in Molecular Biology, **1254** Neuronal Cell Death: Methods and Protocols (ed. Lossi, L. and Merighi, A.) Springer Science+Business Media New York 2015, pp 269-293
- Moriuchi, S.**, Glorioso, J.C., Maruno, M., Izumoto, S., Wolfe, D., Huang, S., Cohen, J.B. and Yoshimine, T. (2005) *Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant I κ B α and HSV thymidine kinase* Cancer Gene Ther., **12**, 487-496 (2005)
- Segura, M.M.**, Kamen, A.A. and Garnier, A. (2011) *Overview of current scalable methods for purification of viral vectors* In, Viral Vectors for Gene Therapy: Methods and Protocols, Methods in Molecular Biology, **737** (eds. Merten O.W. and Al-Rubeai, M.) Springer Science+Business Media, pp 89-116

Publications on Epstein-Barr virus

B cell apoptosis/transformation

- Campion, E.M.**, Hakimjavadi, R., Loughran, S.T., Phelan, S., Smith, S.M., D'Souza, B.N., Tierney, R.J., Bell, A.I., Cahill, P.A. and Walls, D. (2014) *Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β 1-induced B cell apoptosis* J. Virol., **88**, 5001–5013
- Hernando, H.**, Islam, A.B.M.M.K., Rodríguez-Ubreva, J., Forné, I., Ciudad, L., Imhof, A., Shannon-Lowe, C. and Ballestar, E. (2014) *Epstein–Barr virus-mediated transformation of B cells induces global chromatin changes independent to the acquisition of proliferation* Nucleic Acids Res., **42**, 249–263
- Tierney, R.J.**, Nagra, J., Rowe, M., Bell, A.I. and Rickinson, A.B. (2015) *The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation* J. Virol., **89**, 2483-2493

Cellular notch

- Rowe, M.**, Raithatha, S. and Shannon-Lowe, C. (2014) *Counteracting effects of cellular notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions* J. Virol., **88**, 12065–12076

EBNA

- Rowe, M.**, Raithatha, S. and Shannon-Lowe, C. (2014) *Counteracting effects of cellular notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions* J. Virol., **88**, 12065–12076
- Tierney, R.J.**, Kao, K-Y., Nagra, J.K. and Rickinson, A.B. (2011) *Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains* J. Virol., **85**, 12362–12375

Genome

Shannon-Lowe, C., Adland, E., Bell, A.I., Delecluse, H-J., Rickinson, A.B. and Rowe, M. (2009) *Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification* J. Virol., **83**, 7749-7760

Infection

Long, H.M., Leese, A.M., Chagoury, O.L., Connerty, S.R., Quarcoopome, J., Quinn, L.L., Shannon-Lowe, C. and Rickinson, A.B. (2011) *Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition* J. Immunol., **187**, 92–101

Shannon-Lowe, C. and Rowe, M. (2011) *Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection* Plos Pathog., **5**: e1001338

Transcription

Fitzsimmons, L., Bell, A. and Rowe, M., Tierney, R.J., Shannon-Lowe, C.D., (2015) *Unexpected patterns of Epstein-Barr virus transcription revealed by a High throughput PCR array for absolute quantification of viral mRNA* Virology 474, 117–130

Vaccine

Ruiss, R., Jochum, S., Wanner, G., Reisbach, G., Hammerschmidt, W. and Zeidler, R. (2011) *A virus-like particle-based Epstein-Barr virus vaccine* J. Virol., **85**, 13105–13113

Mini-Review MV04: 3rd edition, February 2017

Alere Technologies AS

Axis-Shield Density Gradient Media
is a brand of Alere Technologies AS